{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:02:22Z","timestamp":1779973342195,"version":"3.53.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12328-026-02354-9","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:40:31Z","timestamp":1777880431000},"page":"467-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Covert hepatic encephalopathy in cirrhosis: implications for early diagnosis and appropriate management"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-6142","authenticated-orcid":false,"given":"Chisato","family":"Saeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Toyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Torisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2354_CR1","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMra1600561","volume":"375","author":"EF Wijdicks","year":"2016","unstructured":"Wijdicks EF. Hepatic encephalopathy. N Engl J Med. 2016;375:1660\u201370.","journal-title":"N Engl J Med"},{"key":"2354_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217\u201331.","journal-title":"J Hepatol"},{"key":"2354_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","volume":"61","author":"American Association for the Study of Liver Diseases; European Association for the Study of the Liver","year":"2014","unstructured":"American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642\u201359.","journal-title":"J Hepatol"},{"key":"2354_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77:807\u201324.","journal-title":"J Hepatol"},{"key":"2354_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/apt.14824","volume":"48","author":"C Labenz","year":"2018","unstructured":"Labenz C, Baron JS, Toenges G, Schattenberg JM, Nagel M, Sprinzl MF, et al. Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Aliment Pharmacol Ther. 2018;48:313\u201321.","journal-title":"Aliment Pharmacol Ther"},{"key":"2354_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1111\/j.1572-0241.2007.01424.x","volume":"102","author":"JS Bajaj","year":"2007","unstructured":"Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102:1903\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/ajg.2010.413","volume":"106","author":"E Rom\u00e1n","year":"2011","unstructured":"Rom\u00e1n E, C\u00f3rdoba J, Torrens M, Torras X, Villanueva C, Vargas V, et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol. 2011;106:476\u201382.","journal-title":"Am J Gastroenterol"},{"key":"2354_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/1751-2980.13246","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang J, Deng MJ, Shi PM, Peng Y, Wang XH, Tan W, et al. Covert hepatic encephalopathy is associated with aggressive disease progression and poor survival in patients with cirrhosis. J Dig Dis. 2023;24:681\u201390.","journal-title":"J Dig Dis"},{"key":"2354_CR9","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.3748\/wjg.v23.i34.6321","volume":"23","author":"AJ Wang","year":"2017","unstructured":"Wang AJ, Peng AP, Li BM, Gan N, Pei L, Zheng XL, et al. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients. World J Gastroenterol. 2017;23:6321\u20139.","journal-title":"World J Gastroenterol"},{"key":"2354_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s00535-025-02232-0","volume":"60","author":"T Miwa","year":"2025","unstructured":"Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, et al. Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey. J Gastroenterol. 2025;60:866\u201376.","journal-title":"J Gastroenterol"},{"key":"2354_CR11","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jhep.2020.07.013","volume":"73","author":"CF Rose","year":"2020","unstructured":"Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526\u201347.","journal-title":"J Hepatol"},{"key":"2354_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cld.451","volume":"5","author":"M Munk Lauridsen","year":"2015","unstructured":"Munk Lauridsen M, Vilstrup H. Diagnosing covert hepatic encephalopathy. Clin Liver Dis (Hoboken). 2015;5:71\u20134.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2354_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/hepr.12864","volume":"47","author":"T Kawaguchi","year":"2017","unstructured":"Kawaguchi T, Konishi M, Kato A, Kato M, Kooka Y, Sawara K, et al. Updating the neuropsychological test system in Japan for the elderly and in a modern touch screen tablet society by resetting the cut-off values. Hepatol Res. 2017;47:1335\u20139.","journal-title":"Hepatol Res"},{"key":"2354_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00535-022-01925-0","volume":"57","author":"T Hanai","year":"2022","unstructured":"Hanai T, Nishimura K, Miwa T, Maeda T, Nakahata Y, Imai K, et al. A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis. J Gastroenterol. 2022;57:981\u20139.","journal-title":"J Gastroenterol"},{"key":"2354_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/jpen.2222","volume":"46","author":"T Miwa","year":"2022","unstructured":"Miwa T, Hanai T, Nishimura K, Maeda T, Ogiso Y, Imai K, et al. Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. JPEN J Parenter Enter Nutr. 2022;46:858\u201366.","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"2354_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/hepr.12873","volume":"47","author":"T Hanai","year":"2017","unstructured":"Hanai T, Shiraki M, Watanabe S, Kochi T, Imai K, Suetsugu A, et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Res. 2017;47:1359\u201367.","journal-title":"Hepatol Res"},{"key":"2354_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/hep.26309","volume":"58","author":"JS Bajaj","year":"2013","unstructured":"Bajaj JS, Thacker LR, Heuman DM, Fuchs M, Sterling RK, Sanyal AJ, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58:1122\u201332.","journal-title":"Hepatology"},{"key":"2354_CR18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.cgh.2014.05.011","volume":"13","author":"JS Bajaj","year":"2015","unstructured":"Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, et al. Validation of encephalapp, smartphone-based stroop test, for the diagnosis of covert hepatic encephalopathy. Clin Gastroenterol Hepatol. 2015;13:1828\u201335.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2354_CR19","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/hep4.1738","volume":"5","author":"T Hanai","year":"2021","unstructured":"Hanai T, Shiraki M, Nishimura K, Miwa T, Maeda T, Ogiso Y, et al. Usefulness of the stroop test in diagnosing minimal hepatic encephalopathy and predicting overt hepatic encephalopathy. Hepatol Commun. 2021;5:1518\u201326.","journal-title":"Hepatol Commun"},{"key":"2354_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cgh.2021.12.047","volume":"21","author":"C Acharya","year":"2023","unstructured":"Acharya C, Shaw J, Duong N, Fagan A, McGeorge S, Wade JB, et al. QuickStroop, a shortened version of encephalapp, detects covert hepatic encephalopathy with similar accuracy within one minute. Clin Gastroenterol Hepatol. 2023;21:136\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2354_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2478\/jtim-2020-0034","volume":"8","author":"L Ridola","year":"2020","unstructured":"Ridola L, Faccioli J, Nardelli S, Gioia S, Riggio O. Hepatic encephalopathy: diagnosis and management. J Transl Int Med. 2020;8:210\u20139.","journal-title":"J Transl Int Med"},{"key":"2354_CR22","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","volume":"13","author":"KR Patidar","year":"2015","unstructured":"Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13:2048\u201361.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2354_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/jhep.2002.30957","volume":"35","author":"G Kircheis","year":"2002","unstructured":"Kircheis G, Wettstein M, Timmermann L, Schnitzler A, H\u00e4ussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35:357\u201366.","journal-title":"Hepatology"},{"key":"2354_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.dld.2018.01.133","volume":"50","author":"M Barone","year":"2018","unstructured":"Barone M, Shahini E, Iannone A, Viggiani MT, Corvace V, Principi M, et al. Critical flicker frequency test predicts overt hepatic encephalopathy and survival in patients with liver cirrhosis. Dig Liver Dis. 2018;50:496\u2013500.","journal-title":"Dig Liver Dis"},{"key":"2354_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1053\/j.gastro.2008.07.021","volume":"135","author":"JS Bajaj","year":"2008","unstructured":"Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology. 2008;135:1591\u2013600.","journal-title":"Gastroenterology"},{"key":"2354_CR26","doi-asserted-by":"publisher","first-page":"e0277829","DOI":"10.1371\/journal.pone.0277829","volume":"17","author":"T Miwa","year":"2022","unstructured":"Miwa T, Hanai T, Nishimura K, Maeda T, Tajirika S, Imai K, et al. A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis. PLoS ONE. 2022;17:e0277829.","journal-title":"PLoS ONE"},{"key":"2354_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44355-024-00011-x","volume":"1","author":"D Jakhar","year":"2024","unstructured":"Jakhar D, Sarin SK, Kaur S. Gut microbiota and dynamics of ammonia metabolism in liver disease. npj Gut Liver. 2024;1:1\u20138.","journal-title":"npj Gut Liver"},{"key":"2354_CR28","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","volume":"74","author":"V Arroyo","year":"2021","unstructured":"Arroyo V, Angeli P, Moreau R, Jalan R, Cl\u00e0ria J, Trebicka J, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670\u201385.","journal-title":"J Hepatol"},{"key":"2354_CR29","doi-asserted-by":"publisher","first-page":"100352","DOI":"10.1016\/j.jhepr.2021.100352","volume":"3","author":"W Claeys","year":"2021","unstructured":"Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, et al. The neurogliovascular unit in hepatic encephalopathy. JHEP Rep. 2021;3:100352.","journal-title":"JHEP Rep"},{"key":"2354_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2003.10.016","volume":"40","author":"DL Shawcross","year":"2004","unstructured":"Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247\u201354.","journal-title":"J Hepatol"},{"key":"2354_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11011-006-9042-1","volume":"22","author":"DL Shawcross","year":"2007","unstructured":"Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22:125\u201338.","journal-title":"Metab Brain Dis"},{"key":"2354_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cld.445","volume":"5","author":"TH Tranah","year":"2015","unstructured":"Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis (Hoboken). 2015;5:59\u201363.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"Suppl 1","key":"2354_CR33","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jceh.2014.06.004","volume":"5","author":"DR ldridge","year":"2015","unstructured":"ldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5(Suppl 1):S7\u201320.","journal-title":"J Clin Exp Hepatol"},{"key":"2354_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.14218\/JCTH.2019.00025","volume":"7","author":"V Jaeger","year":"2019","unstructured":"Jaeger V, DeMorrow S, McMillin M. The direct contribution of astrocytes and microglia to the pathogenesis of hepatic encephalopathy. J Clin Transl Hepatol. 2019;7:352\u201361.","journal-title":"J Clin Transl Hepatol"},{"key":"2354_CR35","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/glia.20504","volume":"55","author":"R Reinehr","year":"2007","unstructured":"Reinehr R, G\u00f6rg B, Becker S, Qvartskhava N, Bidmon HJ, Selbach O, et al. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia. 2007;55:758\u201371.","journal-title":"Glia"},{"key":"2354_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.abb.2013.05.004","volume":"536","author":"V Lachmann","year":"2013","unstructured":"Lachmann V, G\u00f6rg B, Bidmon HJ, Keitel V, H\u00e4ussinger D. Precipitants of hepatic encephalopathy induce rapid astrocyte swelling in an oxidative stress dependent manner. Arch Biochem Biophys. 2013;536:143\u201351.","journal-title":"Arch Biochem Biophys"},{"key":"2354_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/hep.23656","volume":"52","author":"B G\u00f6rg","year":"2010","unstructured":"G\u00f6rg B, Qvartskhava N, Bidmon HJ, Palomero-Gallagher N, Kircheis G, Zilles K, et al. Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy. Hepatology. 2010;52:256\u201365.","journal-title":"Hepatology"},{"key":"2354_CR38","first-page":"196","volume":"56","author":"C Sfarti","year":"2020","unstructured":"Sfarti C, Ciobica A, Balmus IM, Ilie OD, Trifan A, Petrea O, et al. Systemic oxidative stress markers in cirrhotic patients with hepatic encephalopathy: possible connections with systemic ammoniemia. Med (Kaunas). 2020;56:196.","journal-title":"Med (Kaunas)"},{"key":"2354_CR39","doi-asserted-by":"publisher","first-page":"BSR20222524","DOI":"10.1042\/BSR20222524","volume":"43","author":"R Zhu","year":"2023","unstructured":"Zhu R, Liu L, Zhang G, Dong J, Ren Z, Li Z. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis. Biosci Rep. 2023;43:BSR20222524.","journal-title":"Biosci Rep"},{"key":"2354_CR40","doi-asserted-by":"publisher","first-page":"595759","DOI":"10.3389\/fcimb.2020.595759","volume":"10","author":"Z Chen","year":"2021","unstructured":"Chen Z, Ruan J, Li D, Wang M, Han Z, Qiu W, Wu G. The role of intestinal bacteria and gut-brain axis in hepatic encephalopathy. Front Cell Infect Microbiol. 2021;10:595759.","journal-title":"Front Cell Infect Microbiol"},{"key":"2354_CR41","doi-asserted-by":"publisher","first-page":"1717696","DOI":"10.3389\/fcimb.2025.1717696","volume":"15","author":"L Chang","year":"2025","unstructured":"Chang L, Liu Y, Li H, Yan J, Wu W, Chen N, et al. Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications. Front Cell Infect Microbiol. 2025;15:1717696.","journal-title":"Front Cell Infect Microbiol"},{"key":"2354_CR42","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.3390\/nu14245261","volume":"14","author":"A Gudan","year":"2022","unstructured":"Gudan A, Jamio\u0142-Milc D, Hawry\u0142kowicz V, Skonieczna-\u017bydecka K, Stachowska E. The prevalence of small intestinal bacterial overgrowth in patients with non-alcoholic liver diseases: NAFLD, NASH, fibrosis, cirrhosis-a systematic review, meta-analysis and meta-regression. Nutrients. 2022;14:5261.","journal-title":"Nutrients"},{"key":"2354_CR43","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s11011-024-01402-y","volume":"39","author":"Y Ntuli","year":"2024","unstructured":"Ntuli Y, Shawcross DL. Infection, inflammation and hepatic encephalopathy from a clinical perspective. Metab Brain Dis. 2024;39:1689\u2013703.","journal-title":"Metab Brain Dis"},{"key":"2354_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2354_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jceh.2018.04.011","volume":"9","author":"S DeMorrow","year":"2019","unstructured":"DeMorrow S. Bile acids in hepatic encephalopathy. J Clin Exp Hepatol. 2019;9:117\u201324.","journal-title":"J Clin Exp Hepatol"},{"key":"2354_CR46","doi-asserted-by":"publisher","first-page":"114436","DOI":"10.1016\/j.ab.2021.114436","volume":"643","author":"E Williams","year":"2022","unstructured":"Williams E, Chu C, DeMorrow S. A critical review of bile acids and their receptors in hepatic encephalopathy. Anal Biochem. 2022;643:114436.","journal-title":"Anal Biochem"},{"key":"2354_CR47","doi-asserted-by":"publisher","first-page":"718783","DOI":"10.3389\/fphys.2021.718783","volume":"12","author":"T Sauerbruch","year":"2021","unstructured":"Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile acids, liver cirrhosis, and extrahepatic vascular dysfunction. Front Physiol. 2021;12:718783.","journal-title":"Front Physiol"},{"key":"2354_CR48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ebiom.2018.10.030","volume":"37","author":"G Xie","year":"2018","unstructured":"Xie G, Wang X, Jiang R, Zhao A, Yan J, Zheng X, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018;37:294\u2013306.","journal-title":"EBioMedicine"},{"key":"2354_CR49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.dld.2014.01.159","volume":"46","author":"M Quinn","year":"2014","unstructured":"Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, DeMorrow S. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis. 2014;46:527\u201334.","journal-title":"Dig Liver Dis"},{"key":"2354_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fncel.2017.00191","volume":"11","author":"M McMillin","year":"2017","unstructured":"McMillin M, Frampton G, Grant S, Khan S, Diocares J, Petrescu A, et al. Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice. Front Cell Neurosci. 2017;11:191.","journal-title":"Front Cell Neurosci"},{"key":"2354_CR51","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbrc.2003.07.016","volume":"313","author":"H Moriwaki","year":"2004","unstructured":"Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun. 2004;313:405\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2354_CR52","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.3390\/jcm9103239","volume":"9","author":"C Saeki","year":"2020","unstructured":"Saeki C, Kanai T, Nakano M, Oikawa T, Torisu Y, Saruta M, et al. Low serum branched-chain amino acid and insulin-like growth factor-1 levels are associated with sarcopenia and slow gait speed in patients with liver cirrhosis. J Clin Med. 2020;9:3239.","journal-title":"J Clin Med"},{"key":"2354_CR53","first-page":"899","volume":"11","author":"C Saeki","year":"2021","unstructured":"Saeki C, Tsubota A. Influencing factors and molecular pathogenesis of sarcopenia and osteosarcopenia in chronic liver disease. Life (Basel). 2021;11:899.","journal-title":"Life (Basel)"},{"key":"2354_CR54","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3748\/wjg.v29.i19.2905","volume":"29","author":"G Marrone","year":"2023","unstructured":"Marrone G, Serra A, Miele L, Biolato M, Liguori A, Grieco A, et al. Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: evidence and uncertainties. World J Gastroenterol. 2023;29:2905\u201315.","journal-title":"World J Gastroenterol"},{"key":"2354_CR55","doi-asserted-by":"publisher","first-page":"18162","DOI":"10.1073\/pnas.1317049110","volume":"110","author":"J Qiu","year":"2013","unstructured":"Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-\u03baB-mediated mechanism. Proc Natl Acad Sci U S A. 2013;110:18162\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2354_CR56","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/jcsm.12212","volume":"8","author":"H Nishikawa","year":"2017","unstructured":"Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle. 2017;8:915\u201325.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2354_CR57","doi-asserted-by":"publisher","first-page":"690","DOI":"10.14309\/ajg.0000000000002563","volume":"119","author":"XH Lv","year":"2024","unstructured":"Lv XH, Lu Q, Deng K, Yang JL, Yang L. Prevalence and characteristics of covert\/minimal hepatic encephalopathy in patients with liver cirrhosis: a systematic review and meta-analysis. Am J Gastroenterol. 2024;119:690\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2354_CR58","first-page":"23","volume":"11","author":"CA Philips","year":"2019","unstructured":"Philips CA, Rajesh S, Augustine P, Padsalgi G, Ahamed R. Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options. Hepat Med. 2019;11:23\u201334.","journal-title":"Hepat Med"},{"key":"2354_CR59","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1111\/liv.14660","volume":"40","author":"R Greinert","year":"2020","unstructured":"Greinert R, Zipprich A, Sim\u00f3n-Talero M, Stangl F, Ludwig C, Wienke A, et al. Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Liver Int. 2020;40:3093\u2013102.","journal-title":"Liver Int"},{"key":"2354_CR60","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/hep.20905","volume":"42","author":"O Riggio","year":"2005","unstructured":"Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42:1158\u201365.","journal-title":"Hepatology"},{"key":"2354_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/hep.20095","volume":"39","author":"C Wein","year":"2004","unstructured":"Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39:739\u201345.","journal-title":"Hepatology"},{"key":"2354_CR62","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1038\/s41598-024-54951-8","volume":"14","author":"T Miwa","year":"2024","unstructured":"Miwa T, Hanai T, Hirata S, Nishimura K, Unome S, Nakahata Y, et al. Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis. Sci Rep. 2024;14:4307.","journal-title":"Sci Rep"},{"key":"2354_CR63","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3390\/jcm14061858","volume":"14","author":"K Koyano","year":"2025","unstructured":"Koyano K, Atsukawa M, Tsubota A, Kondo C, Miwa T, Namisaki T, et al. Association between laboratory values and covert hepatic encephalopathy in patients with liver cirrhosis: a multicenter, retrospective study. J Clin Med. 2025;14:1858.","journal-title":"J Clin Med"},{"key":"2354_CR64","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/hepr.13629","volume":"51","author":"Y Kondo","year":"2021","unstructured":"Kondo Y, Iwasa M, Kawaratani H, Miyaaki H, Hanai T, Kon K, et al. Proposal of stroop test cut-off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study. Hepatol Res. 2021;51:674\u201381.","journal-title":"Hepatol Res"},{"key":"2354_CR65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00535-024-02160-5","volume":"60","author":"N Soma","year":"2025","unstructured":"Soma N, Uchida Y, Kouyama JI, Naiki K, Usui N, Sato A, et al. Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis. J Gastroenterol. 2025;60:96\u2013106.","journal-title":"J Gastroenterol"},{"key":"2354_CR66","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/hepr.13601","volume":"51","author":"T Miwa","year":"2021","unstructured":"Miwa T, Hanai T, Toshihide M, Ogiso Y, Imai K, Suetsugu A, et al. Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy. Hepatol Res. 2021;51:662\u201373.","journal-title":"Hepatol Res"},{"key":"2354_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.clnesp.2024.06.055","volume":"63","author":"T Miwa","year":"2024","unstructured":"Miwa T, Hanai T, Hirata S, Nishimura K, Sahashi Y, Unome S, et al. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: a retrospective cohort study. Clin Nutr ESPEN. 2024;63:267\u201373.","journal-title":"Clin Nutr ESPEN"},{"key":"2354_CR68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12876-025-03674-9","volume":"25","author":"W Wongtrakul","year":"2025","unstructured":"Wongtrakul W, Bandidniyamanon W, Charatcharoenwitthaya P. Relationship between Sarcopenia and minimal hepatic encephalopathy in patients with cirrhosis: a prospective observational study. BMC Gastroenterol. 2025;25:88.","journal-title":"BMC Gastroenterol"},{"key":"2354_CR69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/hepr.70036","volume":"56","author":"T Miwa","year":"2026","unstructured":"Miwa T, Ueda H, Miyazaki T, Honda A, Ikegami T, Unome S, et al. Altered serum bile acid pattern as an independent factor for covert and overt hepatic encephalopathy in patients with cirrhosis. Hepatol Res. 2026;56:60\u20139.","journal-title":"Hepatol Res"},{"key":"2354_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.13747","volume":"295","author":"SJ Gairing","year":"2024","unstructured":"Gairing SJ, Mangini C, Zarantonello L, Gioia S, Nielsen EJ, Danneberg S, et al. Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival. J Intern Med. 2024;295:331\u201345.","journal-title":"J Intern Med"},{"key":"2354_CR71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.28598","volume":"64","author":"LL Gluud","year":"2016","unstructured":"Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis. Hepatology. 2016;64:908\u201322.","journal-title":"Hepatology"},{"key":"2354_CR72","doi-asserted-by":"publisher","first-page":"e00612","DOI":"10.1002\/mbo3.612","volume":"7","author":"S Zhai","year":"2018","unstructured":"Zhai S, Zhu L, Qin S, Li L. Effect of lactulose intervention on gut microbiota and short chain fatty acid composition of C57BL\/6J mice. Microbiologyopen. 2018;7:e00612.","journal-title":"Microbiologyopen"},{"key":"2354_CR73","first-page":"CD003044","volume":"4","author":"LL Gluud","year":"2016","unstructured":"Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044.","journal-title":"Cochrane Database Syst Rev"},{"key":"2354_CR74","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/hep.31708","volume":"74","author":"P Caraceni","year":"2021","unstructured":"Caraceni P, Vargas V, Sol\u00e0 E, Alessandria C, de Wit K, Trebicka J, et al. The use of rifaximin in patients with cirrhosis. Hepatology. 2021;74:1660\u201373.","journal-title":"Hepatology"},{"key":"2354_CR75","doi-asserted-by":"publisher","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE. 2013;8:e60042.","journal-title":"PLoS ONE"},{"key":"2354_CR76","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jhep.2021.08.004","volume":"75","author":"PP Bloom","year":"2021","unstructured":"Bloom PP, Tapper EB, Young VB, Lok AS. Microbiome therapeutics for hepatic encephalopathy. J Hepatol. 2021;75:1452\u201364.","journal-title":"J Hepatol"},{"key":"2354_CR77","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1038\/ctg.2016.44","volume":"7","author":"DJ Kang","year":"2016","unstructured":"Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, et al. Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin Transl Gastroenterol. 2016;7:e187.","journal-title":"Clin Transl Gastroenterol"},{"key":"2354_CR78","doi-asserted-by":"publisher","first-page":"e0323359","DOI":"10.1371\/journal.pone.0323359","volume":"20","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang X, Xiao Y, Wu Z, Wang Y. Efficacy and safety of rifaximin in preventing hepatic encephalopathy: a systematic review and meta-analysis. PLoS ONE. 2025;20:e0323359.","journal-title":"PLoS ONE"},{"key":"2354_CR79","doi-asserted-by":"publisher","first-page":"e0267647","DOI":"10.1371\/journal.pone.0267647","volume":"17","author":"J Fu","year":"2022","unstructured":"Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0267647.","journal-title":"PLoS ONE"},{"key":"2354_CR80","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.cgh.2019.08.047","volume":"18","author":"RK Dhiman","year":"2020","unstructured":"Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:800\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2354_CR81","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/jcm11061571","volume":"11","author":"H Kawaratani","year":"2022","unstructured":"Kawaratani H, Kondo Y, Tatsumi R, Kawabe N, Tanabe N, Sakamaki A, et al. Long-Term efficacy and safety of rifaximin in japanese patients with hepatic encephalopathy: a multicenter retrospective study. J Clin Med. 2022;11:1571.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"2354_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","volume":"79","author":"RF Butterworth","year":"2019","unstructured":"Butterworth RF, McPhail MJW. L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs. 2019;79(Suppl 1):31\u20137.","journal-title":"Drugs"},{"key":"2354_CR83","first-page":"CD012410","volume":"5","author":"ET Goh","year":"2018","unstructured":"Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410.","journal-title":"Cochrane Database Syst Rev"},{"key":"2354_CR84","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s11011-016-9826-x","volume":"31","author":"BC Sharma","year":"2016","unstructured":"Sharma BC, Singh J. Probiotics in management of hepatic encephalopathy. Metab Brain Dis. 2016;31:1295\u2013301.","journal-title":"Metab Brain Dis"},{"key":"2354_CR85","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1111\/liv.16081","volume":"44","author":"YL Zhou","year":"2024","unstructured":"Zhou YL, Pu ST, Xiao JB, Luo J, Xue L. Meta-analysis of probiotics efficacy in the treatment of minimum hepatic encephalopathy. Liver Int. 2024;44:3164\u201373.","journal-title":"Liver Int"},{"key":"2354_CR86","doi-asserted-by":"publisher","first-page":"1379333","DOI":"10.3389\/fmed.2024.1379333","volume":"11","author":"X Yang","year":"2024","unstructured":"Yang X, Lei L, Shi W, Li X, Huang X, Lan L, et al. Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials. Front Med (Lausanne). 2024;11:1379333.","journal-title":"Front Med (Lausanne)"},{"key":"2354_CR87","first-page":"CD008716","volume":"2","author":"R Dalal","year":"2017","unstructured":"Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716.","journal-title":"Cochrane Database Syst Rev"},{"key":"2354_CR88","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cgh.2015.09.028","volume":"14","author":"S Maharshi","year":"2016","unstructured":"Maharshi S, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol. 2016;14:454\u201360.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2354_CR89","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172\u201393.","journal-title":"J Hepatol"},{"key":"2354_CR90","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clnu.2022.03.027","volume":"41","author":"G Konstantis","year":"2022","unstructured":"Konstantis G, Pourzitaki C, Chourdakis M, Kitsikidou E, Germanidis G. Efficacy of branched chain amino acids supplementation in liver cirrhosis: a systematic review and meta-analysis. Clin Nutr. 2022;41:1171\u201390.","journal-title":"Clin Nutr"},{"key":"2354_CR91","doi-asserted-by":"publisher","first-page":"749969","DOI":"10.3389\/fnut.2022.749969","volume":"9","author":"A Ismaiel","year":"2022","unstructured":"Ismaiel A, Bucsa C, Farcas A, Leucuta DC, Popa SL, Dumitrascu DL. Effects of branched-chain amino acids on parameters evaluating sarcopenia in liver cirrhosis: systematic review and meta-analysis. Front Nutr. 2022;9:749969.","journal-title":"Front Nutr"},{"key":"2354_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clnesp.2024.03.011","volume":"61","author":"E Sobhy","year":"2024","unstructured":"Sobhy E, Kamal MM, Saad Y, Saleh DA, Elgohary R, Hassan MS. Effect of branched-chain amino acid supplementation and exercise on quadriceps muscle quantity and quality in patients with cirrhosis as assessed by ultrasonography: a randomized controlled trial. Clin Nutr ESPEN. 2024;61:108\u201318.","journal-title":"Clin Nutr ESPEN"},{"key":"2354_CR93","first-page":"CD001939","volume":"1","author":"L Aamann","year":"2026","unstructured":"Aamann L, Deshpande N, Dam G, Les I, Marchesini G, Borre M, et al. Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev. 2026;1:CD001939.","journal-title":"Cochrane Database Syst Rev"},{"key":"2354_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2019.11.009","volume":"74","author":"K Katayama","year":"2020","unstructured":"Katayama K. Zinc and protein metabolism in chronic liver diseases. Nutr Res. 2020;74:1\u20139.","journal-title":"Nutr Res"},{"key":"2354_CR95","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40795-025-01239-3","volume":"12","author":"Y Gong","year":"2026","unstructured":"Gong Y, Yang Z, Sun G, Xue X, Zhang X. Zinc supplementation in liver cirrhosis: meta-analysis of its effect on biochemical and clinical outcomes. BMC Nutr. 2026;12:10.","journal-title":"BMC Nutr"},{"key":"2354_CR96","first-page":"414","volume":"2","author":"G Bresci","year":"1993","unstructured":"Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993;2:414\u20136.","journal-title":"Eur J Med"},{"key":"2354_CR97","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.nut.2014.04.018","volume":"30","author":"K Katayama","year":"2014","unstructured":"Katayama K, Saito M, Kawaguchi T, Endo R, Sawara K, Nishiguchi S, et al. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial. Nutrition. 2014;30:1409\u201314.","journal-title":"Nutrition"},{"key":"2354_CR98","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.31557\/APJCP.2021.22.9.2879","volume":"22","author":"R Janyajirawong","year":"2021","unstructured":"Janyajirawong R, Vilaichone RK, Sethasine S. Efficacy of zinc supplement in minimal hepatic encephalopathy: a prospective, randomized controlled study (Zinc-MHE trial). Asian Pac J Cancer Prev. 2021;22:2879\u201387.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2354_CR99","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12937-019-0461-3","volume":"18","author":"YC Shen","year":"2019","unstructured":"Shen YC, Chang YH, Fang CJ, Lin YS. Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutr J. 2019;18:34.","journal-title":"Nutr J"},{"key":"2354_CR100","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/nu12071915","volume":"12","author":"T Hanai","year":"2020","unstructured":"Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M. Usefulness of carnitine supplementation for the complications of liver cirrhosis. nutrients. 2020;12:1915.","journal-title":"Nutrients"},{"key":"2354_CR101","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/jgh.14497","volume":"34","author":"T Wang","year":"2019","unstructured":"Wang T, Suzuki K, Kakisaka K, Onodera M, Sawara K, Takikawa Y. L-carnitine prevents ammonia-induced cytotoxicity and disturbances in intracellular amino acid levels in human astrocytes. J Gastroenterol Hepatol. 2019;34:1249\u201355.","journal-title":"J Gastroenterol Hepatol"},{"key":"2354_CR102","first-page":"1097","volume":"10","author":"J Tani","year":"2026","unstructured":"Tani J, Moriya A, Tomonari T, Ogawa C, Tsutsui A, Morishita A, et al. Long-term effects of L-carnitine on hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis: a multicenter retrospective study. Eur J Gastroenterol Hepatol. 2026;10:1097.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2354_CR103","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s10620-008-0238-6","volume":"53","author":"M Malaguarnera","year":"2008","unstructured":"Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci. 2008;53:3018\u201325.","journal-title":"Dig Dis Sci"},{"key":"2354_CR104","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3109\/00365521.2011.565067","volume":"46","author":"M Malaguarnera","year":"2011","unstructured":"Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011;46:750\u20139.","journal-title":"Scand J Gastroenterol"},{"key":"2354_CR105","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3904\/kjim.2021.338","volume":"37","author":"EL Yoon","year":"2022","unstructured":"Yoon EL, Ahn SB, Jun DW, Cho YK, Song DS, Jeong JY, et al. Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Korean J Intern Med. 2022;37:757\u201367.","journal-title":"Korean J Intern Med"},{"key":"2354_CR106","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hep4.1207","volume":"2","author":"M Ohara","year":"2018","unstructured":"Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, et al. L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun. 2018;2:906\u201318.","journal-title":"Hepatol Commun"},{"key":"2354_CR107","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/hep4.1309","volume":"3","author":"A Hiramatsu","year":"2019","unstructured":"Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun. 2019;3:348\u201355.","journal-title":"Hepatol Commun"},{"key":"2354_CR108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.acra.2025.09.049","volume":"33","author":"X Wang","year":"2026","unstructured":"Wang X, Wang Z, Luo B, Lv Y, Han G. Efficacy and safety of spontaneous portosystemic shunts embolization for hepatic encephalopathy: a meta-analysis. Acad Radiol. 2026;33:147\u201356.","journal-title":"Acad Radiol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02354-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:02:52Z","timestamp":1779969772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02354-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02354-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}